Journal of Parkinsons Disease

Papers
(The TQCC of Journal of Parkinsons Disease is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Clinical Trial Highlights: Modulators of Mitochondrial Function107
This is NOT the End for Immunotherapy in Parkinson’s Disease – A Perspective from Early Drug Development Scientists97
Chronotropic Incompetence in Parkinson’s Disease: A Possible Marker of Severe Disease Phenotype?85
One world, one goal: Advocacy and policy for a unified Parkinson's response81
Creation of a machine learning-based model for early identification of mild cognitive impairment risk in Parkinson's disease: A PD research center-based population study75
A prospective analysis of falls in Parkinson's disease: Does physical capacity moderate the relationship between walking amount and falls rates?69
Feasibility and potential effectiveness of an exergame program for people with moderate to advanced Parkinson's disease: A pilot randomized controlled trial65
One-year practice effects predict long-term cognitive outcomes in Parkinson's disease63
When Parkinson's disease interferes in a couple's life: A qualitative study62
Acknowledgment to reviewers 202561
Introduction: The Earliest Phase of Parkinson’s Disease: Possibilities for Detection and Intervention57
Impact and management of cognition on speech and swallow function in Parkinson's disease57
Levodopa-Induced dyskinesia in Latin America: Prevalence and associated clinical factors in the LARGE-PD cohort55
A framework to standardize gait study protocols in Parkinson's disease51
Evolution of disease modifying therapy clinical trial design and therapeutic endpoints for Parkinson's disease47
Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression46
Clinical Trial Highlights – Aerobic Exercise for Parkinson’s Disease44
Effects of Very Low- and High-Frequency Subthalamic Stimulation on Motor Cortical Oscillations During Rhythmic Lower-Limb Movements in Parkinson’s Disease Patients42
May Bradykinesia Features Aid in Distinguishing Parkinson’s Disease, Essential Tremor, And Healthy Elderly Individuals?41
Reply to the Letter to the Editor: Stefani A, “Is it too early to Underrate Genetic onto PD Pathogenesis? Reflections on History”40
The fixel GI Parkinson's research and integrated support model (PRISM)38
Post-Traumatic Stress Disorder and Risk of Parkinson’s Disease in a Veteran Cohort38
Anxiety is associated with increased risk of suicidality in Parkinson's disease36
Longitudinal change in swallow function in patients with Parkinson's disease (PD)36
A monoclonal antibody-based immunoassay reinforces DOPA decarboxylase in cerebrospinal fluid as a diagnostic biomarker for Parkinson's disease with potential prognostic value36
Are Preformed Fibrils a Model of Parkinson’s Disease?36
Atrophy-related corticospinal changes in advanced Parkinson's disease are associated with the genetic etiology of the disease34
Rapid Voluntary Blinking as a Clinical Marker of Parkinson’s Disease34
A Coalition to Advance Treatments for Parkinson’s Disease, Dementia with Lewy Bodies, and Related Disorders34
Jellinger K, “Parkinson’s Disease and Dementia with Lewy Bodies: One and the Same”33
What medicines do people with Parkinson's disease want?32
Early-Onset Parkinson’s Disease: Creating the Right Environment for a Genetic Disorder32
Is There an Association Between Parkinson’s Disease and Periodontitis? A Systematic Review and Meta-Analysis32
A possible pathway to freezing of gait in Parkinson's disease31
Cerebral Small Vessel Disease Is Associated with Motor, Cognitive, and Emotional Dysfunction in Multiple System Atrophy31
Ethical Considerations for Identifying Individuals in the Prodromal/Early Phase of Parkinson’s Disease: A Narrative Review29
Real-World Evaluation of the Feasibility, Acceptability and Safety of a Remote, Self-Management Parkinson’s Disease Care Pathway: A Healthcare Improvement Initiative28
Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson’s Disease28
Imaging Biomarkers in Prodromal and Earliest Phases of Parkinson’s Disease28
Neuroinflammation and Immune Changes in Prodromal Parkinson’s Disease and Other Synucleinopathies27
Burden of tremor in Parkinson's disease: A survey study27
Nomogram to Predict the Probability of Functional Dependence in Early Parkinson’s Disease26
Feasibility and Proof-of-Concept of Delivering an Autonomous Music-Based Digital Walking Intervention to Persons with Parkinson’s Disease in a Naturalistic Setting26
Nigral Iron Deposition Influences Disease Severity by Modulating the Effect of Parkinson’s Disease on Brain Networks26
Twenty-five-year experience with apomorphine pump in Parkinson's disease: A real-life long-term retrospective tolerance study26
Localized Pantothenic Acid (Vitamin B5) Reductions Present Throughout the Dementia with Lewy Bodies Brain26
DNA Methylation Signature of Aging: Potential Impact on the Pathogenesis of Parkinson’s Disease25
Nomogram for Early Prediction of Parkinson’s Disease Based on microRNA Profiles and Clinical Variables25
Telerehabilitation for early-stage Parkinson's disease: A randomized controlled feasibility trial of individualised real-time physiotherapy delivered via a videoconference platform24
Modulation of Cerebellar Oscillations with Subthalamic Stimulation in Patients with Parkinson’s Disease24
Mortality and causes of death in patients with Parkinson's disease in Taiwan24
Metabolic connectivity of freezing in Parkinson's disease24
Home-Based time-constrained reactive training enhances movement speed in upper and lower limbs in Parkinson's disease: A randomized controlled trial24
Mild cognitive impairment is not predictive of dementia up to 15 years after subthalamic deep brain stimulation in Parkinson's disease24
Rationale and current status of fecal microbiota transplantations for Parkinson's disease23
Burden, Anxiety, and Depression Among Caregivers of Parkinson’s Disease Patients23
The Role of Diet in Parkinson’s Disease22
Taste Impairments in a Parkinson’s Disease Model Featuring Intranasal Rotenone Administration in Mice22
Metabotropic Glutamate Receptor 4 (mGlu 4 ) Positive Allosteric Modulators Lack Efficacy in Rat and Marmoset Models of L-DOPA-Induced Dyskinesia22
Atypical parkinsonian syndromes in French Guiana: Similarities and differences with Caribbean variants21
A glimpse of the end-of-life of people with Parkinson's disease and atypical parkinsonism: A descriptive analysis of electronic health records21
A dose-finding study shows terazosin enhanced energy metabolism in neurologically healthy adults21
Motor Memory Consolidation Deficits in Parkinson’s Disease: A Systematic Review with Meta-Analysis21
Specific Detection of Physiological S129 Phosphorylated α-Synuclein in Tissue Using Proximity Ligation Assay20
Gait Declines Differentially in, and Improves Prediction of, People with Parkinson’s Disease Converting to a Freezing of Gait Phenotype20
Acknowledgment to Reviewers 202220
Hidden Gems in Neurology: The Syndrome of Hemiparkinsonism-Hemiatrophy20
Unveiling the neural network of freezing of gait in Parkinson's disease: A coordinate-based network study19
Non-Pharmacological Interventions for People with Parkinson’s Disease: Are We Entering a New Era?19
Effects of transcutaneous vagus nerve stimulation on anxiety and balance under space constraints in Parkinson's disease with anxiety syndrome: A preliminary study19
Specialized Allied Health Care for Parkinson’s Disease: State of the Art and Future Directions19
Effects of 6 months of endurance exercise on motor function, exercise capacity, and autonomic function based on presence of autonomic dysfunction in individuals with early Parkinson's disease19
Utility of a newly created questionnaire on subtle motor symptoms in high-risk subjects with Parkinson's disease19
“Tip-of-the-Tongue” Phenomenon in Parkinson’s Disease: A Hidden Gem19
Symmetric and Profound Monoaminergic Degeneration in Parkinson’s Disease with Premotor REM Sleep Behavior Disorder19
Enhancing Participant Engagement in Clinical Studies: Strategies Applied in the Personalized Parkinson Project18
Staging Parkinson’s Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life18
Georgina M. Aldridge, Matthew Weber and Lauren Walker recipients of the Parkinson Prize 202517
Integrating virtual reality into multidisciplinary care for Parkinson's disease: A narrative review17
Buspirone regulates cortico-striatal gamma oscillations to ameliorate dyskinesia17
Freezing of gait detection: The effect of sensor type, position, activities, datasets, and machine learning model17
Parkinson’s Pals: A Student-Led Program to Facilitate Intergenerational Connections and Promote Psychosocial Well-Being Among Persons with Parkinson’s Disease17
Reactive astrocyte-related pathogenic genes in Parkinson's disease: A multi-omics Mendelian randomization study17
Enhancing the diagnostic potential of electroretinography in Parkinson's disease: A review of protocol and cohort criteria17
Gastroparesis in Parkinson's disease: Diagnostic and clinical implications for optimizing pharmacological treatment17
A Practical Guide to the Evaluation of Compensation Strategies for Gait Impairment in Parkinson’s Disease16
Structural-Functional Correlates of Response to Pedunculopontine Stimulation in a Randomized Clinical Trial for Axial Symptoms of Parkinson’s Disease16
Sex-specific progression of Parkinson's disease: A longitudinal mixed-models analysis16
Tackling Parkinson’s Disease as a Global Challenge16
Designing the First Trials for Parkinson’s Prevention16
Anxiety-related attentional characteristics and their relation to freezing of gait in people with Parkinson's: Cross-validation of the Adapted Gait Specific Attentional Profile (G-SAP)16
Basal ganglia neurophysiological markers of non-motor symptoms in Parkinson's disease: A systematic review16
Regulatory endorsement for the application of α-synuclein seed amplification assay as a susceptibility and risk biomarker for clinical trials targeting synucleinopathies16
Incretin Mimetics Restore the ER-Mitochondrial Axis and Switch Cell Fate Towards Survival in LUHMES Dopaminergic-Like Neurons: Implications for Novel Therapeutic Strategies in Parkinson’s Disease16
Remote Delivery of Allied Health Therapies in Parkinson’s Disease15
Gender Distribution in Deep Brain Stimulation for Parkinson’s Disease: The Effect of Awake versus Asleep Surgery15
Feasibility and acceptability of PDConnect, a multi-component intervention to support physical activity in people with Parkinson's disease: A mixed methods study15
Emerging Role of Environmental Epitranscriptomics and RNA Modifications in Parkinson’s Disease15
Discontinuation or acute unplanned cessation of oral dopaminergic medications in persons with Parkinson's disease: A practice review15
Reduced Thickness of the Retina in de novo Parkinson’s Disease Shows A Distinct Pattern, Different from Glaucoma14
Kinematic Effects of Combined Subthalamic and Dorsolateral Nigral Deep Brain Stimulation in Parkinson’s Disease14
40-Year Incidence of Early-Onset Parkinson’s Disease in Southeast Minnesota14
Diffuse putaminal degeneration without iron deposition in multiple system atrophy14
Discordance between actual and perceived balance ability relates to quality of life and global cognition in a clinical sample of Parkinson patients14
Off-State dyspnea induced by diaphragmatic-chest wall asynchrony in Parkinson's disease: A novel observation and review of the literature14
Unmet needs in the pharmacological management of motor symptoms in Parkinson's disease14
Non-Pharmacological Treatment of Autonomic Dysfunction in Parkinson’s Disease and Other Synucleinopathies14
Exploring the link between personality dimensions and non-motor fluctuations in Parkinson's disease14
Anxiety in Parkinson’s Disease Is Associated with Changes in Brain Structural Connectivity14
Place of death in Parkinson's disease: A systematic review and meta-analysis of associated factors14
Trichloroethylene: An Invisible Cause of Parkinson’s Disease?14
Quantitative Susceptibility Mapping and Free Water Imaging of Substantia Nigra in Parkinson’s Disease14
Spinal Cord Stimulation for Gait Disorders in Parkinson’s Disease14
Natural Health Products for Symptomatic Relief of Parkinson’s Disease: Prevalence, Interest, and Awareness13
Prevalence of Concomitant Pathologies in Parkinson’s Disease: Implications for Prognosis, Diagnosis, and Insights into Common Pathogenic Mechanisms13
Analysis of α-synuclein seed amplification assay in carriers of GBA1 and LRRK2 pathogenic variants13
Echocardiographic insights into cardiovascular autonomic dysfunction in Parkinson's disease13
Distinct Patterns of Gene Expression Changes in the Colon and Striatum of Young Mice Overexpressing Alpha-Synuclein Support Parkinson’s Disease as a Multi-System Process13
Non-Motor Symptom Management: Insights into Adherence to Treatment Guidelines in Parkinson’s Disease Patients13
Advice to People with Parkinson’s in My Clinic: Orthostatic Hypotension13
Intestinal biomarkers, microbiota composition, and genetic predisposition to inflammatory bowel disease as predictors of Parkinson's disease manifestation13
Inflammasome Activation in Parkinson’s Disease13
Longitudinal Cohort Study of Verbatim-Reported Postural Instability Symptoms as Outcomes for Online Parkinson’s Disease Trials12
Immunological Features of LRRK2 Function and Its Role in the Gut-Brain Axis Governing Parkinson’s Disease12
Therapeutic Strategies for Immune Transformation in Parkinson’s Disease12
Pediatric-onset PRKN disease: New insights into an understudied population12
Stem cell treatments and Parkinson's disease: Science and misconceptions12
Association Between Body Mass Index Changes and All-Cause Mortality in Parkinson’s Disease12
The Use of Image Guided Programming to Improve Deep Brain Stimulation Workflows with Directional Leads in Parkinson’s Disease12
E326K GBA polymorphism is associated with clinical and pathological features of synucleinopathy in the absence of overt Parkinson's disease or Lewy body 12
Non-Pharmacological Interventions for Depression and Anxiety in Parkinson’s Disease12
Mycobacterium bovis Infection of a Deep Brain Stimulation System Following Intravesical Bacillus Calmette-Guérin (BCG) Instillation12
The potential of distributed diagnostics for the early detection of Parkinson's disease12
Mapping Cholinergic Synaptic Loss in Parkinson’s Disease: An [18F]FEOBV PET Case-Control Study12
RAGE Against the Glycation Machine in Synucleinopathies: Time to Explore New Questions12
Obstructive sleep apnea, periodic limb movements, and REM sleep without atonia are common in Parkinson's disease and correlate with motor symptom burden12
Assessing the Role of Locus Coeruleus Degeneration in Essential Tremor and Parkinson’s Disease with Sleep Disorders12
New insights from a Malaysian real-world deep brain stimulation cohort11
Relating movement behaviours and non-motor characteristics in people with Parkinson's disease: A compositional data analysis approach11
Biofluid Detection of Pathological α -Synuclein in the Prodromal Phase of Synucleinopathies11
Worsening of Parkinson’s Disease After Termination of COVID-19 Quarantine Cannot Be Reversed Despite Resumption of Physiotherapy11
Quantitative measures of total and phosphorylated alpha-synuclein in skin tissue as potential biomarkers for synucleinopathies11
The road towards faster development of novel pharmacotherapies for persons with Parkinson's disease11
Proposed mechanisms of neuroprotection for nicotine in Parkinson's disease11
Novel insights into relationships between metabolic covariance patterns of FDG-PET data and clinical status in Parkinson's disease using partial least squares correlation analysis11
Acknowledgment to Reviewers 202311
Letter to the Editor: Is It Too Early to Underrate Genetics onto PD Pathogenesis? Reflections on History11
A PLAN to address the Parkinson pandemic11
Depressive symptoms can negatively influence patient reported disease severity after subthalamic nucleus stimulation for Parkinson's disease11
Pain Fluctuations in Parkinson’s Disease and Their Association with Motor and Non-Motor Fluctuations11
The impact of diet on Parkinson's disease risk: A data-driven analysis in a large Italian case-control population11
How Information Affects Patients with Parkinson’s Disease: A Scoping Review of the Literature11
Parkinson's disease drug therapies in the clinical trial pipeline: 2015–202411
Infections and Changes in Commensal Bacteria and the Pathogenesis of Parkinson’s Disease11
Why the Gut Microbiome Must Be Considered When Evaluating the Impact of Pesticides on Parkinson’s Disease Risk10
Evaluation and management of male sexual dysfunction in Parkinson's disease: A clinical road map10
Development of a Screening Tool for Assessing Sexual Difficulties Among Patients with Parkinson’s Disease: The PD-SDS10
Preparing for Parkinson’s disease prevention trials: Current progress and future directions10
Full recovery after severe bacterial encephalitis and brain abscess following deep brain stimulation surgery for Parkinson's disease10
Screening Tools for Sarcopenia in Mild to Moderate Parkinson’s Disease: Assessing the Accuracy of SARC-F and Calf Circumference10
Motor outcomes in unilateral, bilateral rapid, and bilateral delayed staging deep brain stimulation for Parkinson’s disease10
Increasing trends in utilization of physical and occupational therapy services in early Parkinson's disease10
Deep brain stimulation in alpha-synuclein models of Parkinson's disease: Bridging the translational gap10
Dopaminergic Cell Replacement for Parkinson’s Disease: Addressing the Intracranial Delivery Hurdle10
Colonoscopy and Subsequent Risk of Parkinson’s Disease10
Mucuna pruriens in untreated Parkinson's disease in sub-Saharan Africa: A 12-month, multicenter, randomized, controlled trial10
Early bone health assessment is indicated in Parkinson's: Risk factor analysis in a UK population-based cohort study10
Oscillation-Specific Nodal Differences in Parkinson’s Disease Patients with Anxiety10
Machine Learning-Based Classification of Parkinson’s Disease Patients Using Speech Biomarkers10
Using Extracellular miRNA Signatures to Identify Patients with LRRK2-Related Parkinson’s Disease10
0.071445941925049